Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1596 of 5804
-
Could a new stomach surgery help control diabetes in gastric cancer patients?
Disease control CompletedRecently, the concept of "Onco-metabolic surgery" has emerged, and it is a theory that if anastomosis bypassing the duodenum and upper jejunum is performed after gastrectomy in gastric cancer patients with type 2 diabetes, diabetes can be expected to improve. The authors would li…
Phase: PHASE3 • Sponsor: Korea University Guro Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug shows promise for rare Muscle-Weakening disease
Disease control CompletedThe purpose of this study is to initially observe the safety and effectivity of RC18 in Participants with systemic myasthenia gravis.
Phase: PHASE2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Online CBT offers new hope for first responders battling PTSD
Symptom relief Recruiting nowThis study evaluates two Internet-delivered cognitive behavioural therapy (ICBT) interventions: one for symptoms of posttraumatic stress disorder (PTSD) and one for symptoms of anxiety, depression, and PTSD. Both interventions have been tailored for Canadian public safety personn…
Phase: NA • Sponsor: University of Regina • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
Gene therapy offers hope for rare blood disorder
Disease control CompletedThis is an open-label Phase I trial to evaluate the safety of a hematopoietic cell-based gene therapy for patients with Pyruvate Kinase Deficiency (PKD).
Phase: PHASE1 • Sponsor: Rocket Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:53 UTC
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control TerminatedThis is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Syndrome (hrMDS). Patients enrolling in the Phase 1 dose escalation of the study …
Phase: PHASE1, PHASE2 • Sponsor: Curis, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New cocktail of drugs shows promise in hepatitis b trial
Disease control CompletedThis is a study designed to evaluate the safety, tolerability and efficacy of New Molecular Entity (NME) combination therapies in Chronic Hepatitis B (CHB) participants with preserved liver function and without significant fibrosis/cirrhosis. The platform design allows comparison…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 26, 2026 18:59 UTC
-
Lab-Grown tumor clones could guide cancer therapy
Knowledge-focused Recruiting nowThe emergence of tumor organoid cultures in recent years has made it possible to widen the repertoire of available preclinical tumor models and to bridge the gap between cell lines and tumors of xenografted patients in mice (PDXs).These organoids have the advantages of being able…
Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New vaccine strategy aims to shield lymphoma patients from deadly infections
Prevention CompletedPneumococcal infections remain frequent and potentially fatal. To prevent them, two anti-pneumococcal vaccines exist: a 13-valent conjugate vaccine (Prevenar®) and a 23-valent polysaccharide vaccine (Pneumovax®). For their utilization, several studies approved a prime-boost strat…
Phase: PHASE3 • Sponsor: University Hospital, Tours • Aim: Prevention
Last updated Jun 27, 2026 09:05 UTC
-
Old heart drug gets a second look: can low doses save lives?
Disease control CompletedDigoxin is the oldest, market-authorized drug for heart failure (HF), and very cheap. A large trial with digoxin, the DIG trial, executed in the early nineties revealed a highly significant reduction in HF hospitalizations, but no effect on mortality. A post-hoc analysis of the D…
Phase: PHASE4 • Sponsor: University Medical Center Groningen • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Blood test could reveal how lung cancer evolves during treatment
Knowledge-focused CompletedTo evaluate the predictive value of ctDNA in response, relapse for patients treated with immune checkpoint inhibitors or targeted therapy for ALK, ROS1, MET ex14 skipping.
Sponsor: Geneplus-Beijing Co. Ltd. • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Nanoparticles + radiation: new hope against tough pancreatic cancer?
Disease control OngoingTo find the recommended dose of NBTXR3 that can be given in combination with radiation therapy to patients with pancreatic cancer. To learn if the dose NBTXR3 found in Part 1 can help to control the disease.
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug aims to reignite immune attack on Hard-to-Treat cancers
Disease control Recruiting nowThe purpose of this study is to describe the safety, tolerability and early signs of efficacy of the antibody-cytokine fusion protein IL12-L19L19 in patients with advanced or metastatic solid carcinomas, after previous immune checkpoint blockade therapy. The primary objective of…
Phase: PHASE1 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Zapping cancer spots could delay stronger drugs
Disease control Recruiting nowEvery year, 12500 primary renal cell carcinoma (RCC) are diagnosed in France. Metastases occur in half of RCC patients. Management of metastatic RCC is based on systemic treatments (targeted therapies/immunotherapy). However, resistance to systemic treatment is frequent. In case…
Phase: PHASE2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Scientists hunt for smarter treatments for kids with leukemia
Knowledge-focused Recruiting nowPrognosis of children with leukemia, the most common pediatric cancer, has improved markedly. Yet, relapse still occurs in 15-40% of patients with a probability of survival of \<50%, which is unlikely to be boosted by intensification of standard chemotherapy due to overwhelming t…
Sponsor: Chinese University of Hong Kong • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
New drug ST101 takes on Hard-to-Treat cancers
Disease control OngoingThis is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors. The study consists of two phases: a phase 1 dose escalation/regimen…
Phase: PHASE1, PHASE2 • Sponsor: Sapience Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Can a targeted drug shrink tumors when immunotherapy fails?
Disease control Recruiting nowThis is a Phase II treatment, non-randomized, open label clinical trial to study the efficacy of the Cetuximab when administered as single agent in recurrent/ metastatic head and neck squamous cell carcinoma after the failure or intolerance of immuno-oncology or immuno-oncology c…
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can we treat sicker lung cancer patients the same as healthier ones?
Disease control Recruiting nowThis pilot study is configured as a non-inferiority comparison of Performance Status 2 patients with Performance Status 0-1 patients, with the goal of demonstrating non-inferiority in terms of efficacy (progression-free survival, overall survival) and safety (rates of adverse eve…
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Acupuncture may slash opioid use in cancer patients
Symptom relief OngoingThe purpose of this study is to find out whether acupuncture treatments can reduce the need for opioid medication when managing pain caused by chemotherapy. The study will compare the effects of adding acupuncture to usual pain management with those of usual pain management alone…
Phase: PHASE3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 07:55 UTC
-
Hope fades: trial of Tay-Sachs drug venglustat terminated early
Disease control TerminatedPrimary Objectives: Primary population (adult participants with late-onset GM2 gangliosidosis): To assess the efficacy and pharmacodynamics (PD) of daily oral dosing of venglustat when administered over a 104-week period Secondary population (participants with juvenile/adolesce…
Phase: PHASE3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Smarter prostate cancer detection: new combo test aims to reduce unnecessary biopsies
Diagnosis OngoingThe purpose of this research study is to determine if the interpretation of multiparametric MRI (mpMRI) with an algorithm called habitat risk score (HRS) in combination with a panel of blood and urine biomarkers is more effective at detecting prostate cancer than standard of care…
Sponsor: University of Miami • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC